FDA warns of MMS dangers
This article was originally published in The Tan Sheet
Executive Summary
FDA warns consumers that Miracle Mineral Solution, also marketed as MMS, produces an industrial bleach when used as directed and can cause serious harm. Several reported health injuries related to the product include "severe nausea, vomiting and life-threatening low blood pressure from dehydration," the agency says in a July 30 alert. MMS, which Hialeah, Fla.-based 7Seas promoted as treating multiple diseases including HIV, hepatitis, H1N1, cancer, the common cold and acne, is sold online by multiple independent distributors. Instructions on product labels direct users to mix the 28 percent sodium chlorite solution with an acidic liquid such as citrus juice, a mixture that produces chlorine dioxide, a potent bleach used to strip textiles. FDA continues to investigate and may pursue civil or criminal enforcement action. FDA sent 7Seas a warning letter in April (1"The Tan Sheet" April 26, 2010)
You may also be interested in...
7Seas cancer claims attract FDA attention
Supplement claims made by 7Seas LLC on Web sites such as 1www.AlternateCancerCure.com and 2www.TreatAllCancer.com elicit an April 5 warning letter from FDA's Florida District office. The letter to Norman Hem of the Hialeah, Fla.-based firm alleges that products, including Jade Windscreen, Apricot Seeds and Miracle Mineral Supplement, make disease claims causing them to be unapproved drugs. According to the agency, 7Seas' claims include, "The most powerful, PROVEN cancer treatment and prevention products EVER known to humankind" and "MMS is the answer to ... malaria, hepatitis A, B and C, colds, herpes, TB, most cancer, flu, pneumonia, as well as many other illnesses and diseases." The firm had 15 days to respond to FDA
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.